Business Wire

International Experts Commend Riyadh’s Lifestyle Transformation Projects

5.5.2019 15:08:00 EEST | Business Wire | Press release

Share

A panel of prominent International experts from various academic and professional fields convened yesterday to discuss Riyadh’s USD23 billion investment in the recently announced 4 Grand Projects that will transform the city and improve the wellbeing of millions of citizens in the capital city.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190505005026/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Group picture of the international experts attending Riyadh’s Lifestyle Transformation Forum (Photo: AETOSWire)

The Subject Matter Expert (SME) Forum took place at the Exhibition Centre King Fahad Library Plaza on 1st and 2nd May 2019. Discussion centered on a number of topics, including sustainable urban development, conservation, socio-economic well-being, art and culture, and the facilitation of a healthy lifestyle for all citizens.

The 4 Wellbeing Projects will greatly improve Saudis’ way of life by providing a greener, healthier environment and by encouraging participation in cultural and sporting life, in line with the Kingdom’s Vision 2030. These four projects are part of a massive development plan for the capital Riyadh, highlighting the Kingdom's leadership in sustainable urbanization and environmental management.

The Projects are: King Salman Park – one of the world’s largest urban parks with a land area of 13 km2, roughly four times that of Central Park in New York. The park, in addition to its large green spaces, will include a national theatre, opera house and art academy, and will host entertainment, environmental and cultural events. Green Riyadh – an urban greening project that will reduce CO2 levels and cool the city by up to 2°C. Green Riyadh will see 7.5 million trees planted in gardens, parks, mosques, schools and around the capital’s governmental and health sectors. Riyadh Art – a citywide gallery that will include 1,000 works of art and interactive installations, placed in residential areas, public parks, transport facilities and on Riyadh’s roads. Sports Boulevard – the first of its kind in the region, will feature 135 km of multi-purpose track for walking, running, cycling and horse riding.

“What I’ve seen over these two days is very much at the cutting edge and redefines what a city could be. What Riyadh is doing here I haven’t seen anywhere else in the world – where the planning is so integrated and well thought through, and innovative thinking is so evident. Riyadh is setting the standard. I commend these 4 Grand Projects,” John Rossant, Chairman & Founder, New Cities Foundation.

“Every one of these Wellbeing Projects is quite extraordinary. Riyadh will be transformed in ways that you and I can’t fully understand. They will transform this city not just in its infrastructure and facilities, but will transform health, culture and the very way citizens live their lives,” said Dr. David Griggs, Professor, Sustainable Development Institute, Monash University.

“The scale of these city projects is really impressive. Planting a few trees is nice. Maybe planting a couple of blocks is worthy. But it’s only when you get to the scale of 7.5 million trees and 9% green coverage of the city that you can actually change the climate and cool the city down,” John Englander, Oceanographer & Author, commenting on the 7.5 million trees that will be planted as part of the Riyadh Green Project.

www.riyadhksp.sa/en/

www.riyadhalmasar.sa/en/

www.riyadhart.sa/en/

www.riyadhgreen.sa/en/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Riyadh Development Authority
Riyadh, Kingdom of Saudi Arabia
Arch. Khalid Al-Hazani, Director, Architectural Projects Program & Public Affairs
+966544777772, hazzani@ada.gov.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye